2024-11-04 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1. Performance Comparison:**

Abbott Laboratories (ABT) is a multinational healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

As of today, ABT has a cumulative return of 111.83% compared to the S&P 500 (VOO) which has a cumulative return of 131.78%. This indicates that ABT has underperformed the S&P 500 by **-19.95%**. 

**Analyzing the alpha and beta:**

* **Alpha:**  ABT's alpha has been volatile over the past years. It exhibited positive alpha in 2017, 2019, 2020, and 2021 indicating outperformance relative to the market. However, negative alpha in 2016, 2018, 2022, and 2023 implies underperformance compared to the market. 
* **Beta:** ABT's beta has been relatively stable, ranging from 0.0 to 2.1, suggesting moderate market sensitivity. A beta greater than 1 indicates the stock is more volatile than the market, while a beta less than 1 indicates it's less volatile. 

**2. Recent Price Movement:**

* **Closing Price:** $118.6
* **5-day Moving Average:** $114.78
* **20-day Moving Average:** $115.94
* **60-day Moving Average:** $114.15

The current price is above all three moving averages, indicating a short-term upward trend.

**3. Technical Indicators:**

* **RSI:** 53.43.  This suggests a neutral market sentiment, neither oversold nor overbought.
* **PPO:** -0.14.  This negative value indicates that the price momentum is weakening, but not necessarily signaling a downturn.
* **Delta_Previous_Relative_Divergence:** 8.96 (+). This suggests that the stock is experiencing short-term upward momentum. 
* **Expected Return:** 0.0%. The expected return is based on long-term (2+ years) investment and reflects potential outperformance compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue  |
|-------------|-------|----------|
| 2024-10-31 | 0.94  | 10.63 B$ |
| 2024-07-31 | 0.74  | 10.38 B$ |
| 2024-05-02 | 0.7   | 9.96 B$ |
| 2023-11-01 | 0.82  | 10.14 B$ |
| 2024-10-31 | 0.82  | 10.14 B$ |

The most recent earnings were announced on 2024-10-31, with an EPS of 0.94. While the exact earnings expectations are not provided, the company has consistently exceeded revenue expectations in recent quarters.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter        | Revenue  | Profit Margin |
|-------------|----------|---------------|
| 2024-09-30 | $10.63B | 55.83%        |
| 2024-06-30 | $10.38B | 55.64%        |
| 2024-03-31 | $9.96B  | 55.21%        |
| 2023-12-31 | $10.24B | 55.51%        |
| 2023-09-30 | $10.14B | 54.60%        |

Abbott Laboratories consistently demonstrates strong profitability with high profit margins. Revenue growth has been steady, indicating a healthy business operation.

**2) Capital and Profitability:**

| Quarter        | Equity   | ROE  |
|-------------|----------|------|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

The company's ROE has been consistently above 3%, indicating efficient use of shareholder capital. The steady increase in equity signifies strong financial health.

**6. News and Recent Issues:**

* **Recent Earnings News:** You did not provide any specific news sources for earnings releases. I would recommend checking reputable financial news websites like Bloomberg, Reuters, or the company's investor relations website for the latest earnings news.
* **Recent Market Outlook:** 
    * FINBOLD provides a "Strong Buy" rating for ABT based on its strong financials and growth potential.
    * Analysts generally view ABT as a stable and reliable company with consistent earnings and a solid track record. 
    * The stock is considered a defensive play in the healthcare sector, meaning it may hold its value during market downturns.

**7. Overall Analysis:**

Abbott Laboratories is a well-established healthcare company with a history of strong financial performance. It boasts steady revenue growth, high profit margins, and efficient capital utilization. While the recent underperformance compared to the S&P 500 might raise some concerns, the company's solid fundamentals, growth potential, and defensive nature position it as a valuable investment option for long-term investors. 

**8. English Report:**

This analysis suggests that ABT has underperformed the S&P 500 in recent years.  However, the company's strong financials, high profit margins, and consistent revenue growth make it a solid long-term investment opportunity, especially for those seeking defensive plays in the healthcare sector. 

Remember that this analysis is based on the data provided and should not be considered as financial advice. Please consult with a qualified financial professional before making any investment decisions. 
